Comvest Credit Partners Agents Senior Credit Facility to Support the Refinancing of Peer Advisors, Parent Company of Celink, by Further Global Capital Management
'We are pleased to support Celink's veteran management team and complete another transaction with Further Global,' said Jack Wyatt, a Principal at Comvest Credit Partners.
Celink provides a comprehensive set of services to reverse mortgage lenders and borrowers. Its services include loan onboarding, data validation, call center, payment processing, lines of credit disbursements, tax and insurance monitoring, occupancy monitoring, investor and regulator reporting, foreclosure and REO management, and record retention. Celink is based in Lansing, Mich., and Tulsa, Okla.
'Celink is the leading player in a complex and highly regulated niche industry and provides critical services to lenders and borrowers through its proprietary technology servicing platform,' said Jack Wyatt, a Principal at Comvest Credit Partners. 'We are pleased to support Celink's veteran management team and complete another transaction with Further Global, a highly experienced financial services-focused private equity sponsor. We look forward to working together to support Celink's continued growth as well as on other opportunities in the sector.'
'Comvest Credit Partners worked collaboratively to deliver a creative financing structure that provides both capital at scale and addresses Celink's unique needs for growth,' said Olivier Sarkozy, Managing Partner of Further Global. 'In addition, the Comvest team's deep understanding of the financial services sector was key to their ability to expeditiously get this deal done.'
About Celink
Celink has been the nation's leading subservicer of reverse mortgages since 2005 and is the subservicer of choice for the nation's largest reverse mortgage lenders. Celink is a Ginnie Mae-approved Participation Agent and Subcontract Servicer for the HMBS program, a Morningstar DBRS approved servicer, as well as a Moody's approved servicer of reverse mortgages ("SQ2" rating). Celink utilizes an innovative servicing platform, ReverseServ Elite, which is fully scalable and supports numerous proprietary reverse mortgage products in addition to FHA's HECM program. For more information, visit www.celink.com.
About Further Global Capital Management
Further Global Capital Management is an employee-owned private equity firm that makes investments in businesses within the business services and financial services industries. Further Global seeks to be a true partner with the management teams with whom it invests with an objective to be the "Capital Partner of Choice" to the industry. Further Global seeks out situations in which its extensive network, operational expertise and capital can drive significant value. Further Global has raised over $3 billion of cumulative committed and invested capital. For more information, visit www.furtherglobal.com.
About Comvest Credit Partners
Comvest Credit Partners, the direct lending platform of Comvest Partners, focuses on providing flexible financing solutions to middle-market companies. Comvest Credit Partners provides senior secured, unitranche, and second lien capital to sponsored and non-sponsored companies in support of growth, acquisitions, buyouts, refinancings, and recapitalizations, with credit facilities up to $300 million-plus. For more information, please visit comvest.com/direct-lending.
About Comvest Partners
Comvest Partners ('Comvest') is a private investment firm that has provided equity and debt capital to well-positioned middle-market companies throughout North America since 2000. Through its private equity, direct lending and opportunistic credit investment platforms, Comvest offers tailored investment solutions across the capital structure along with deep industry expertise, operating resources, a collaborative approach, and significant transaction experience as an active investor. In 2025, Comvest Partners proudly celebrates 25 years of investment management leadership, and today manages $15.7 billion in assets, with over $16.8 billion invested since inception. Comvest Partners is based in West Palm Beach, with offices in Chicago and New York City. For more information, please visit comvest.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
an hour ago
- New York Post
Costco won't sell abortion pills after outcry from religious groups
Costco said it will not offer abortion pills at any of its more than 500 pharmacies nationwide, a move celebrated by religious groups that lobbied against the drug being dispensed by retailers. The Washington state-based wholesaler insisted its decision was based on a lack of customer interest in the medication, Mifepristone, which together with another medicine called misoprostol, is used to end a pregnancy within 10 weeks of gestation. It didn't address whether pressure from conservative organizations influenced the move. 4 A Costco location in the US, one of more than 500 company pharmacies that will not provide Mifepristone. Getty Images A coalition of religious groups including Idaho-based Inspire Investing, the conservative legal organization Alliance Defending Freedom and treasurers and other financial officials from Ohio, Texas, Nevada and Utah had contacted the retailer last year requesting it not carry the drug, according to Bloomberg News. 'It's a very significant win and it's one we hope to build on this coming year,' said Michael Ross, an attorney working with Alliance Defending Freedom's corporate engagement division. Ross indicated the coalition plans to target Walgreens Boots Alliance and CVS next. Both pharmacy chains currently provide mifepristone in states that don't have abortion restrictions. People living in states that have severely limited abortion can obtain the medication by mail from states without such bans. The religious investors sent similar requests last year to Kroger, Walmart and Albertsons alongside Costco, urging them against carrying the medication. Kroger responded that it has never provided abortion pills and continues monitoring regulatory developments. Neither Walmart nor Albertsons currently stocks the medicine. Costco's decision intensifies the ongoing debate about access to the medication. 4 Mifepristone tablets are part of a two-drug regimen to terminate early pregnancies. AP New York City Comptroller Brad Lander had written to various retailers in July last year representing city pension funds, encouraging them to pursue authorization for offering the drug. 'Costco's decision to refuse to dispense mifepristone is disappointing and short-sighted,' a representative from Lander's office told Bloomberg. 'Failure to provide access to proven safe and FDA-approved medication under the guise of 'weak demand' risks isolating customers and undermines the company's credibility.' The Post has sought comment from Costco and Lander. The religious organizations have promised to continue to ramp up pressure. 'We have this momentum,' said Tim Schwarzenberger, who leads corporate engagement at Inspire, which manages the biggest religious exchange-traded fund. 'Now there is a chance to turn to some of the other retailers.' doesn't presently sell the medication, and Schwarzenberger indicated his organization will work to maintain that status. 4 A patient prepares to take mifepristone, which blocks progesterone to end an early-stage pregnancy. AP Amazon didn't provide a response to inquiries. Walgreens declined to comment but referenced information on its website stating: 'The US Supreme Court's ruling on mifepristone access allows Walgreens to continue to dispense mifepristone under the FDA guidelines.' CVS confirmed it distributes mifepristone in certain states where permitted after completing what it called a thorough certification procedure. 'We have a long history of supporting and advancing women's health and we remain focused on meeting their unique health needs. This includes providing access to safe, legal, and evidence-based reproductive health services,' the company stated. The elimination of nationwide abortion protections has resulted in uneven access throughout the US, leading telehealth providers to address some service gaps. Various state legislators have proposed legislation to designate mifepristone as a restricted drug and reduce telehealth availability. According to tracking by the Guttmacher Institute, a nonprofit research organization, lawmakers introduced 32 proposals to prohibit medication abortion and 38 to restrict access during the 2025 legislative period, representing the highest number since the overturn of Roe v. Wade. Data from the Society of Family Planning, an abortion rights organization, shows most abortions in America still occur either at medical facilities or through prescriptions from doctors filled at pharmacies like CVS or Walgreens. A smaller percentage involves prescriptions delivered by mail. 4 Anti-abortion demonstrators rally outside the US Supreme Court in March of last year as debate over medication abortion continues. AP Following increased state-level abortion restrictions, more women have pursued online mifepristone prescriptions for mail delivery. These shipments now represent approximately 25% of American abortions, up from 5 percent before the 2022 Supreme Court decision that ended federal abortion protections. Eight states permitting abortion have enacted protective legislation shielding doctors from prosecution when prescribing mifepristone to patients in states with abortion prohibitions. Ushma Upadhyay, a reproductive sciences professor at the University of California, San Francisco, explained that CVS, Walgreens and similar pharmacies don't provide the medication in states prohibiting abortion, creating difficulties for women seeking the procedure. Telehealth providers can utilize protective laws to ship pills directly to states with restrictions, she noted. This has generated legal disputes. A Texas resident filed a lawsuit in July against a California physician for prescribing abortion medication to his girlfriend. A New York doctor faces criminal charges in Louisiana and a lawsuit from Texas's Attorney General for shipping pills to patients in those states.
Yahoo
6 hours ago
- Yahoo
Acquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics Stock
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is one of the . A definitive merger agreement announced in the first week of August drives a short-term surge in the stocks' performance. A scientist in a lab coat, holding a beaker of a biopharmaceutical creation. Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is a commercial-stage biopharmaceutical company focused on radioimmunotherapy and antibody-based oncology treatments. The company's lead product, DANYELZA® (naxitamab-gqgk), is the first FDA-approved therapy for relapsed or refractory high-risk neuroblastoma in bone or bone marrow. Operating from New Jersey, the company also advances a robust pipeline of investigational cancer therapies. On August 5, 2025, SERB Pharmaceuticals agreed to acquire Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) in an all-cash transaction valued at approximately $412 million. SERB will commence a tender offer to purchase all outstanding shares of the company's common stock for $8.60 per share in cash. This offer represents an approximate 105% premium to Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)' closing share price on August 4, 2025, the last full trading day before the transaction announcement. The acquisition includes DANYELZA, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)' lead commercial oncology asset. SERB intends to use it for broadening its existing Rare Oncology portfolio and expanding its investment in the U.S. market. Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)'s stock price soared by 71.43% this week, gaining a dramatic rebound after a 26.80% yearly drop, making it one of the best short-term biotech investments. While we acknowledge the potential of YMAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Indianapolis Star
20 hours ago
- Indianapolis Star
Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates
Click here to register Jaguar CEO Lisa Conte presenting August 20 at Emerging Growth Conference to provide updates on near-term catalysts; Click here to register SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / August 12, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Thursday, August 14, 2025, at 8:30 a.m. Eastern to review second-quarter 2025 financials and provide corporate updates. Participation Instructions for Jaguar Investor Webcast When: Thursday, August 14, 2025 at 8:30 AM Eastern Time Participant Registration & Access Link: Click Here Participation Instructions for Jaguar's Virtual Presentation at the Emerging Growth Conference When: Wednesday, August 20, 2025 from 2:55 – 3:05 PM Eastern Time Where: Online (Click Here) Registration link for conference: Click Here Replay: An archived webcast of the presentation will be made available on and on the Emerging Growth YouTube Channel. About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi ® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about: Jaguar Health, visit Napo Pharmaceuticals, visit Napo Therapeutics, visit Magdalena Biosciences, visit Canalevia-CA1, visit Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram Forward-Looking Statements Certain statements in this press release constitute 'forward-looking statements.' These include statements regarding the expectation that Jaguar will file its 10-Q on August 14, 2025 for the quarter ended June 30, 2025, the expectation that Jaguar will hold an investor webcast on August 14, 2025, and Jaguar's expectation that Jaguar management will present at the August 2025 Emerging Growth Conference. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact: hello@ Jaguar-JAGX SOURCE: Jaguar Health, Inc.
